GRAIL Q2 2026 revenue up 26% to $44.7M; Galleri volume up 35% YoY; net loss $110.2M

GRAIL, Inc.

Total revenue $44.7M (+26% YoY); Galleri test revenue $42.6M (+24% YoY); test volume >61,000 (+35% YoY).
Net loss $110.2M, improved $3.7M (3%) YoY; gross loss $12.6M, improved 29%.
Non-GAAP adjusted gross profit $21.6M (+34% YoY); adjusted EBITDA -$90.3M.
Completed $110M equity financing with Samsung; PMA submitted, FDA advisory committee expected in fall.
Presented NHS-Galleri and PATHFINDER 2 results at ASCO 2026, showing consistent performance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.